The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer
- 1 February 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 29 (2), 509-519
- https://doi.org/10.1158/1055-9965.epi-18-1359
Abstract
Background: Recent efforts to improve outcomes for high-grade serous ovarian cancer, a leading cause of cancer death in women, have focused on identifying molecular subtypes and prognostic gene signatures, but existing subtypes have poor cross-study robustness. We tested the contribution of cell admixture in published ovarian cancer molecular subtypes and prognostic gene signatures. Methods: Gene signatures of tumor and stroma were developed using paired microdissected tissue from two independent studies. Stromal genes were investigated in two molecular subtype classifications and 61 published gene signatures. Prognostic performance of gene signatures of stromal admixture was evaluated in 2,527 ovarian tumors (16 studies). Computational simulations of increasing stromal cell proportion were performed by mixing gene-expression profiles of paired microdissected ovarian tumor and stroma. Results: Recently described ovarian cancer molecular subtypes are strongly associated with the cell admixture. Tumors were classified as different molecular subtypes in simulations where the percentage of stromal cells increased. Stromal gene expression in bulk tumors was associated with overall survival (hazard ratio, 1.17; 95% confidence interval, 1.11–1.23), and in one data set, increased stroma was associated with anatomic sampling location. Five published prognostic gene signatures were no longer prognostic in a multivariate model that adjusted for stromal content. Conclusions: Cell admixture affects the interpretation and reproduction of ovarian cancer molecular subtypes and gene signatures derived from bulk tissue. Elucidating the role of stroma in the tumor microenvironment and in prognosis is important. Impact: Single-cell analyses may be required to refine the molecular subtypes of high-grade serous ovarian cancer.Funding Information
- NIH (RC4CA156551)
- NIH (P30CA006516, R01CA174206)
- NIH (R01CA133057)
- NIH (R03CA191447)
- NIH (U19CA148065, P01CA087969)
- NIH (G12MD007599)
- Breast Cancer Research Program (W81XWH-15-1-0013)
This publication has 49 references indexed in Scilit:
- curatedOvarianData: clinically annotated data for the ovarian cancer transcriptomeDatabase: The Journal of Biological Databases and Curation, 2013
- A Three-Gene Model to Robustly Identify Breast Cancer Molecular SubtypesJNCI Journal of the National Cancer Institute, 2012
- GeneSigDB: a manually curated database and resource for analysis of gene expression signaturesNucleic Acids Research, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- The Gene Expression Barcode: leveraging public data repositories to begin cataloging the human and murine transcriptomesNucleic Acids Research, 2010
- Frozen robust multiarray analysis (fRMA)Biostatistics, 2010
- A Gene Signature Predictive for Outcome in Advanced Ovarian Cancer Identifies a Survival Factor: Microfibril-Associated Glycoprotein 2Cancer Cell, 2009
- Microenvironmental regulation of metastasisNature Reviews Cancer, 2008
- A stromal gene signature associated with inflammatory breast cancerInternational Journal of Cancer, 2007
- Gene expression profiling of human ovarian tumoursBritish Journal of Cancer, 2006